Emory University

Running trials

• Not yet recruiting

  Kidney RISE: Randomized Integrated Supportive CarE Trial

  NCT07741357· Source

• Not yet recruiting

  Integrating Supports to Promote PrEP for Black Adolescents Working With Apps- Atlanta

  NCT07535346· Source

• Not yet recruiting

  Topical Curcumin for HPV Related Cervical Disease

  NCT04266275· Phase 2· Source

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Source

• Not yet recruiting

  Electrophysiologic Mechanisms of Ketamine Antidepressant Response

  NCT07768618· Phase 2· Source

• Recruiting

  A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease

  NCT07778667· Phase 3· Source

• Not yet recruiting

  Hypoxic Red Blood Cells in Sickle Cell Anemia

  NCT06743113· Source

• Not yet recruiting

  Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

  NCT07778602· Early phase 1· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Source

• Recruiting

  A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

  NCT07459634· Phase 2· Source

• Not yet recruiting

  Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease

  NCT07675408· Source

• Enrolling by invitation

  Measurement of Ocular Microtremor With the iTremor Device in a Diverse US Cohort

  NCT07858214· Source

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Source

• Recruiting

  Thrive With Type 1 Diabetes 2026

  NCT07522866· Source

• Not yet recruiting

  Handgrip Exercise Training and CKD

  NCT07094906· Source

• Not yet recruiting

  H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC)

  NCT07484139· Phase 2· Source

• Recruiting

  Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

  NCT07569926· Phase 4· Source

• Recruiting

  An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Phase 2· Source

• Enrolling by invitation

  Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

  NCT07461350· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Source

• Not yet recruiting

  Early Diagnostic Telehealth Pilot for Moderate- and High-Risk Children: Evaluating Assessment Protocols and Efficiency in Georgia's Early Intervention Program

  NCT07623759· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Source

• Recruiting

  A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions

  NCT07422480· Phase 3· Source

• Recruiting

  Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

  NCT07579702· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  Horizon Two: HR NDMM (MMRC-100)

  NCT07053436· Phase 2· Source

• Recruiting

  A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06769698· Phase 2· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

  NCT07332481· Phase 3· Source

• Recruiting

  Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  NCT07379827· Source

• Active, not recruiting

  A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07266441· Phase 2· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Active, not recruiting

  GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

  NCT07228117· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

  NCT07219212· Phase 1· Source

• Recruiting

  A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

  NCT07187973· Phase 1· Source

• Recruiting

  Tofersen in Non-SOD1 ALS

  NCT07294144· Phase 2· Source

• Recruiting

  Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

  NCT07288359· Phase 1/2· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

  NCT07296484· Phase 2· Source

• Recruiting

  A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

  NCT07206225· Phase 1· Source

• Recruiting

  BoxX-NoAF Clinical Trial

  NCT06989775· Source

• Recruiting

  Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

  NCT07143669· Source

• Recruiting

  An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

  NCT07206056· Phase 1/2· Source

• Recruiting

  ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

  NCT06800963· Phase 1/2· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  Study of COYA 302 for the Treatment of ALS

  NCT07161999· Phase 2/3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer10 recruiting
• Lung cancer9 recruiting
• Parkinson disease9 recruiting
• Bladder cancer8 recruiting
• Childhood cancers7 recruiting
• Colorectal cancer7 recruiting
• Head and neck cancer7 recruiting
• Coronary artery disease6 recruiting
• Multiple myeloma6 recruiting
• Type 1 diabetes6 recruiting
• ALS (motor neurone disease)5 recruiting
• Alzheimer disease5 recruiting
• Chronic kidney disease5 recruiting
• Crohn's disease5 recruiting
• Lupus (SLE)5 recruiting
• Stroke5 recruiting
• Acute myeloid leukemia4 recruiting
• Atrial fibrillation4 recruiting
• Depression4 recruiting
• Gastric and esophageal cancer4 recruiting
• HIV4 recruiting
• Myelodysplastic syndromes4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Pancreatic cancer4 recruiting
• Sickle cell disease4 recruiting
• Type 2 diabetes4 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Cervical cancer3 recruiting
• Cystic fibrosis3 recruiting
• Fabry disease3 recruiting
• Glioblastoma3 recruiting
• High blood pressure3 recruiting
• Idiopathic pulmonary fibrosis3 recruiting
• Melanoma3 recruiting
• Metastatic breast cancer3 recruiting
• Ovarian cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Amyloidosis2 recruiting
• Autism2 recruiting
• Endometrial cancer2 recruiting
• Frontotemporal dementia2 recruiting
• Heart failure2 recruiting
• Lewy body dementia2 recruiting
• Multiple sclerosis2 recruiting
• Osteoporosis2 recruiting
• Pompe disease2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Ulcerative colitis2 recruiting
• ANCA-associated vasculitis1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• Epilepsy1 recruiting
• Long COVID and ME/CFS1 recruiting
• Macular degeneration1 recruiting
• Neuroendocrine tumours1 recruiting
• Polycystic kidney disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Schizophrenia1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Simplified Onboarding in Adults With Type 2 Diabetes

  NCT07070830· Source

• Terminated

  VIZ ACCESS HCM - Multi-Site Registry

  NCT07103057· Source

• Completed

  Innovative Automated Insulin Delivery System for Type 2 Diabetes

  NCT06853990· Source

• Completed

  A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

  NCT06791122· Source

• Withdrawn

  REVERSE-Long COVID-19 With Baricitinib Study

  NCT05858515· Phase 3· Source

• Completed

  RECOVER-SLEEP: Platform Protocol

  NCT06404086· Phase 2· Source

• Completed

  Safety Study of PP-007 in Subjects With Acute Ischemic Stroke

  NCT04677777· Phase 1· Source

• Recruiting

  Platform Clinical Study for Conquering Scleroderma

  NCT06195072· Phase 2· Source

• Completed

  Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes

  NCT06127251· Source

• Completed

  Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

  NCT05934526· Phase 3· Source

• Completed

  Improving Sleep and AD Biomarkers

  NCT06029894· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Source

• Completed

  A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

  NCT06019728· Phase 4· Source

• Completed

  Web-based Physical Activity Intervention to Promote Physical Activity

  NCT05803304· Source

• Completed

  HEAL-LAA Clinical Trial

  NCT05809596· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Source

• Completed

  Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening

  NCT06561217· Source

• Recruiting

  Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

  NCT05836259· Phase 1/2· Source

• Terminated

  Achieving Portal Access With Scorpion Post-Approval Study (APASS)

  NCT05765253· Source

• Completed

  A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

  NCT05785832· Source

• Completed

  A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

  NCT05805501· Phase 2· Source

• Terminated

  Effectiveness Trial of Mobile ESI for Toddlers With Autism Identified by Early Screening in Primary Care

  NCT05456139· Source

• Completed

  NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

  NCT05666713· Source

• Completed

  Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

  NCT05624268· Phase 3· Source

• Completed

  ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

  NCT05653271· Phase 1· Source

• Terminated

  Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients

  NCT05068726· Source

• Terminated

  Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

  NCT05306873· Phase 2· Source

• Completed

  Closed Loop Glucose Control in Patients With Type 1 and Type 2 Diabetes

  NCT05644730· Source

• Completed

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Source

• Withdrawn

  ENACT: A Study of ENX-101 as Adjunctive Treatment in Patients With Focal Seizures

  NCT05481905· Phase 2· Source

• Completed

  Improving Sleep and Cognition in Alzheimer's Disease

  NCT05200208· Source

• Completed

  Pharmacy-based Pre-exposure Prophylaxis

  NCT04393935· Source

• Completed

  A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

  NCT05347485· Phase 2· Source

• Completed

  Time in Glucose Hospital Target

  NCT05135676· Source

• Withdrawn

  Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

  NCT05204160· Phase 2· Source

• Terminated

  Prevention of NAFLD in Hispanic Children

  NCT05292352· Source

• Completed

  A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

  NCT05241834· Phase 1· Source

• Completed

  Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)

  NCT05276349· Source

• Completed

  Achieving Portal Access With Scorpion Post-Approval Study 2

  NCT06856655· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Source

• Completed

  Hybrid Effectiveness-Implementation Trial of Guided Relaxation and Acupuncture for Chronic Sickle Cell Disease Pain

  NCT04906447· Phase 2· Source

• Terminated

  A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD

  NCT03919162· Phase 2· Source

• Completed

  A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

  NCT05093933· Phase 3· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· Source

• Terminated

  A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma

  NCT05119335· Phase 1/2· Source

• Terminated

  Study of INCA 0186 in Subjects With Advanced Solid Tumors

  NCT04989387· Phase 1· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Source

• Completed

  A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis

  NCT05006352· Phase 1· Source

• Completed

  Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers

  NCT04948866· Source

• Completed

  Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention

  NCT04923880· Source

Trial sites

• 8400376 - Emory University1 trial
• Duplicate_Emory University /ID# 2215621 trial
• Duplicate_Emory University /ID# 2272991 trial
• Duplicate_Emory University /ID# 2403281 trial
• Emory Univ1 trial
• Emory University324 trials
• Emory University Department of Urology1 trial
• Emory University /ID# 1406651 trial
• Emory University, Nell Hodgson Woodruff School of Nursing1 trial
• Emory University School of Medicine67 trials
• Emory University School Of Medicine - Atlanta1 trial
• Emory University School Of Medicine - Atlanta /ID# 2615291 trial
• Emory University School Of Medicine - Atlanta /ID# 2688321 trial
• Emory University School Of Medicine - Atlanta /ID# 2735221 trial
• Emory University School of Medicine - Atlanta- Site Number : 84000091 trial
• Emory University School of Medicine - Atlanta- Site Number : 84000101 trial
• Emory University School of Medicine: Division of Rheumatology2 trials
• Emory University School of Medicine (Site 0123)1 trial
• Emory University School of Medicine (Site 3043)1 trial
• Emory University School of Medicine (Site 3818)1 trial
• Emory University School of Medicine Site Number : 10051 trial
• Emory University School Of Medicine- Site Number : 8400601 trial
• Emory University School of Nursing2 trials
• Emory University (Site 1030)1 trial
• Rollins School of Public Health, Emory University1 trial
• Emory University2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• HIV479 works · 18 trials
• Stroke409 works · 16 trials
• Alzheimer disease339 works · 20 trials
• Obesity232 works · 6 trials
• Heart failure225 works · 17 trials
• Type 2 diabetes169 works · 12 trials
• Lung cancer151 works · 27 trials
• Prostate cancer136 works · 15 trials
• Tuberculosis117 works · 0 trials
• Schizophrenia111 works · 2 trials
• Atrial fibrillation109 works · 8 trials
• Cystic fibrosis107 works · 9 trials
• Parkinson disease101 works · 13 trials
• Chronic kidney disease101 works · 12 trials
• Sickle cell disease96 works · 12 trials
• Epilepsy90 works · 5 trials
• Coronary artery disease87 works · 16 trials
• Multiple myeloma78 works · 25 trials
• Melanoma74 works · 7 trials
• Liver and biliary tract cancer73 works · 3 trials
• Asthma71 works · 2 trials
• Kidney cancer65 works · 6 trials
• Childhood cancers65 works · 20 trials
• Colorectal cancer58 works · 16 trials
• Triple-negative breast cancer54 works · 7 trials
• Autism49 works · 3 trials
• Ovarian cancer48 works · 7 trials
• Head and neck cancer48 works · 14 trials
• Cervical cancer47 works · 6 trials
• Lupus (SLE)46 works · 15 trials